SEC Form 4 · accession 0001385508-18-000043
OPIANT PHARMACEUTICALS, INC. · OPNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas T. Thomas
Director
Period of report
May 11, 2018
Accepted (ET)
May 15, 2018 · 6:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001385508
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 11, 2018 | M | 7,063 | $10.00 | A | 7,063 | D | |
| Common Stock | May 14, 2018 | S | 3,500 | $18.54 | D | 3,563 | D | |
| Common Stock | May 15, 2018 | S | 800 | $17.53 | D | 2,763 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | $10.00 | May 11, 2018 | M | 15,000 | D | Aug 29, 2017 | Nov 3, 2021 | Common Stock | 7,063 | 8,334 | D |
Explanation of responses
- F1Reflects the net cashless exercise of an option to purchase 15,000 shares, which resulted in the issuance of a net 7,063 shares to the optionee, and an effective reduction of 7,937 shares based on the following formula. Number of shares = number of options times (current stock price of $18.90 less exercise price of $10) divided by the current stock price of $18.90 to fund the cashless exercise of 7,063 options